-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A recent study published in the journal Neurology assessed the dose-response relationship and wavelet of 10, 20, and 40 mg of ponimod using a combined data analysis of the Phase 2 core and extension studies in patients with relapsing multiple sclerosis (RRMS).
In the core study, 464 patients were randomly assigned (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n = 116), or 40 mg of ponimod (n = 119), once daily for 24 weeks
A total of 435 patients received ≥1 dose of ponimod (first randomized dose: 10mg=139, 20mg=145, and 40mg=151)
In conclusion, the control effect of Ponimod 20mg on multiple sclerosis was maintained for about 8 years, and no new safety issues were found
references:
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis Results From Randomized Phase 2b Core and Extension Studies.